DGAP-News

Novavax Prices Public Offering of Common Stock - Seite 2

Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at [phone].

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines and vaccine adjuvants to address a broad range of infectious
diseases worldwide. Using innovative proprietary recombinant nanoparticle
vaccine technology, the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.

Forward-Looking Statements

Statements contained in this release, including those relating to the expected
closing of the offering, and those statements using words such as 'expects' and
'intends' are forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements. These risks and uncertainties include, but
are not limited to: our ability to successfully complete the offering on terms
and conditions satisfactory to us; the possible adverse impact on the market
price of our shares of common stock due to the dilutive effect of the
securities to be sold in the offering; capital market risks; our ability to
raise additional capital when needed; and other risk factors identified from
time to time in the reports we file with Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov. We
caution investors not to place considerable reliance on the forward-looking
statements contained in this press release. The forward-looking statements in
this press release speak only as of the date of this document, and we undertake
no obligation to update or revise any of the statements. Our business is
subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful
consideration to these risks and uncertainties.


CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

06.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Novavax, Inc.


United States
ISIN: US6700021040


End of News DGAP News-Service
---------------------------------------------------------------------
272510 06.06.2014